OptimizeRx Corp. announced that William J. Febbo, Chief Executive Officer and Board Member, will depart the company effective December 31, 2024. Mr. Febbo will provide advisory services through March 31, 2025, to ensure a smooth transition.
Stephen Silvestro, who previously served as the company's President and Chief Commercial Officer, has been appointed as the interim CEO. The Board of Directors has initiated a search process to identify a permanent successor.
The company reaffirmed its financial guidance for the full year 2024, stating that it expects to achieve the higher end of its previously provided revenue and adjusted EBITDA ranges. This indicates confidence in the company's operational performance despite the leadership change.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.